Ophthalmic Pipeline

Calpain Therapeutics is examining the potential for it’s proprietary library of compounds to treat unmet medical needs, relevant for both front and back of the eye diseases.

Front of the Eye #1 (Cataract): Our lead compound, is a proprietary Calpain inhibitor that has been shown to effectively slow down the rate of progression of cataract by 27% in a unique sheep model of the disease in which the animals develop full cataract in about 8 months. It is currently undergoing confirmatory pre-clinical studies in a proprietary human lens model.

Back of the Eye #2 (Retinal Diseases):  Our lead compound is also under pre-clinical examination to treat retinal diseases and protect the retinal tissue by aiding recovery.